Research ArticleArticle
Hydroxychloroquine Suppresses Interferon-inducible Genes and B Cell Activating Factor in Patients With Incomplete and New-onset Systemic Lupus Erythematosus
Wietske M. Lambers, Johanna Westra, Hendrika Bootsma and Karina de Leeuw
The Journal of Rheumatology November 2020, jrheum.200726; DOI: https://doi.org/10.3899/jrheum.200726
Wietske M. Lambers
This study was funded by ReumaNederland (Dutch Arthritis Foundation; grant number 15-1-401). W.M. Lambers, MD, PhD candidate, J. Westra, PhD, H. Bootsma, MD, PhD, K. de Leeuw, MD, PhD, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. No financial support or other benefits from commercial sources for the work reported on in the manuscript, or any other financial interests that any of the authors may have, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work are to be declared. Address correspondence to Dr. W.M. Lambers, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands. Email: w.m.lambers@umcg.nl. Accepted for publication October 26, 2020.
Johanna Westra
This study was funded by ReumaNederland (Dutch Arthritis Foundation; grant number 15-1-401). W.M. Lambers, MD, PhD candidate, J. Westra, PhD, H. Bootsma, MD, PhD, K. de Leeuw, MD, PhD, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. No financial support or other benefits from commercial sources for the work reported on in the manuscript, or any other financial interests that any of the authors may have, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work are to be declared. Address correspondence to Dr. W.M. Lambers, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands. Email: w.m.lambers@umcg.nl. Accepted for publication October 26, 2020.
Hendrika Bootsma
This study was funded by ReumaNederland (Dutch Arthritis Foundation; grant number 15-1-401). W.M. Lambers, MD, PhD candidate, J. Westra, PhD, H. Bootsma, MD, PhD, K. de Leeuw, MD, PhD, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. No financial support or other benefits from commercial sources for the work reported on in the manuscript, or any other financial interests that any of the authors may have, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work are to be declared. Address correspondence to Dr. W.M. Lambers, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands. Email: w.m.lambers@umcg.nl. Accepted for publication October 26, 2020.
Karina de Leeuw
This study was funded by ReumaNederland (Dutch Arthritis Foundation; grant number 15-1-401). W.M. Lambers, MD, PhD candidate, J. Westra, PhD, H. Bootsma, MD, PhD, K. de Leeuw, MD, PhD, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. No financial support or other benefits from commercial sources for the work reported on in the manuscript, or any other financial interests that any of the authors may have, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the work are to be declared. Address correspondence to Dr. W.M. Lambers, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9700 RB Groningen, the Netherlands. Email: w.m.lambers@umcg.nl. Accepted for publication October 26, 2020.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Hydroxychloroquine Suppresses Interferon-inducible Genes and B Cell Activating Factor in Patients With Incomplete and New-onset Systemic Lupus Erythematosus
Wietske M. Lambers, Johanna Westra, Hendrika Bootsma, Karina de Leeuw
The Journal of Rheumatology Nov 2020, jrheum.200726; DOI: 10.3899/jrheum.200726
Hydroxychloroquine Suppresses Interferon-inducible Genes and B Cell Activating Factor in Patients With Incomplete and New-onset Systemic Lupus Erythematosus
Wietske M. Lambers, Johanna Westra, Hendrika Bootsma, Karina de Leeuw
The Journal of Rheumatology Nov 2020, jrheum.200726; DOI: 10.3899/jrheum.200726